

Magle Group sponsors inaugural VENTI Conference in Tokyo, Japan — supporting innovation in vascular embolotherapy and pain interventions

Magle Group is proud to announce its sponsorship of the inaugural Vascular Embolotherapy and Nerve Interventions Targeting Inflammation and Pain (VENTI) Conference, to be held in Tokyo, Japan 7-8 November.

VENTI brings together an esteemed international faculty of regional and global experts in musculoskeletal and pain interventions, highlighting the rapidly advancing field of vascular and nerve embolotherapy for inflammatory and degenerative conditions. The conference aims to foster collaboration, share clinical experiences, and promote new approaches to improving patient outcomes in chronic pain and inflammation management.

Magle Group's sponsorship follows the recently announced positive clinical data demonstrating excellent efficacy and safety of EmboCept® S in Genicular Artery Embolisation (GAE) for the treatment of knee osteoarthritis pain, based on patient data from leading German and Italian centres.

Helena Ossmer Thedius, Chief Marketing & Innovation Officer at Magle Group, commented: "We are delighted to support VENTI and the clinicians who are redefining the standards of care in embolotherapy and pain intervention. The strong and growing clinical evidence around EmboCept® S underscores its potential to play a leading role in the management of osteoarthritis and related inflammatory conditions. As the field expands globally, we are committed to collaborating with medical professionals and supporting education and awareness through initiatives like VENTI."

EmboCept® S, based on Magle Group's proprietary degradable starch microsphere (DSM) technology, is designed to provide effective, temporary embolisation with a proven biocompatibility and safety profile. Its use in musculoskeletal applications such as GAE represents a new frontier in minimally invasive pain therapy, offering an alternative to surgery for patients with limited treatment options.

Magle Group's participation at VENTI reflects its ongoing commitment to advancing science, supporting clinicians, and improving patients' quality of life through innovative and degradable embolic technologies.

About VENTI

The Vascular Embolotherapy and Nerve Interventions Targeting Inflammation and Pain (VENTI) Conference is a new international forum dedicated to exploring the role of vascular and nerve embolotherapy in treating inflammation, pain, and degenerative disorders. The meeting brings together interventional radiologists, pain specialists, and researchers from across the world to discuss the latest developments in this rapidly evolving field.

Contacts

Justin Pierce, CEO, phone +46 (0)70 593 58 21, justin.pierce@maglechemoswed.com

About Us

The Magle Group aims to establish itself as a leader in high-quality life-changing healthcare innovations to meet medical needs through scientific excellence. The Magle Group is founded on strategic acquisitions aimed at driving growth and diversifying risk. Today, the Group includes three operational areas. Magle Chemoswed – a contract development and manufacturing organization (CDMO) with a strong reputation for its high-quality development and manufacturing expertise and Magle PharmaCept – an established sales and marketing company for development and direct sales of the Groups medical technology products. Magle Biopolymers A/S- a specialized manufacturing organization of Dextran technology. Learn more on www.maglechemoswed.com and www.maglegroup.com and www.maglepharmaceut.com and www.maglebiopolymers.com

Vator Securities is the Company's certified adviser on Nasdaq First North Growth Market and can be reached at ca@vatorsec.se or +46 (0)8-580 065 99.

Attachments

[Magle Group sponsors inaugural VENTI Conference in Tokyo, Japan — supporting innovation in vascular embolotherapy and pain interventions](#)